Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 20 million shares of common stock and associated warrants, aiming to raise approximately $10 million to fund research and development activities and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 20,000,000 shares of common stock and Series C and D warrants, priced at $0.50 per share, with total gross proceeds expected to be around $10 million before expenses [1]. - Series C Warrants and Series D Warrants will have an exercise price of $0.50 per share, with Series C Warrants expiring in five years and Series D Warrants expiring in 12 months [2]. - The closing of the offering is anticipated on or about June 27, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [6]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and protected by composition of matter patents in multiple regions [6].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

Core Viewpoint - Kratos Defense & Security Solutions, Inc. has announced an underwritten offering of 12,987,013 shares of common stock at a price of $38.50 per share, aiming to raise approximately $483.75 million in net proceeds for various strategic initiatives [1][2]. Group 1: Offering Details - The offering price is set at $38.50 per share, with expected net proceeds of approximately $483,750,000 after underwriting discounts and commissions [1]. - Kratos has granted underwriters a 30-day option to purchase an additional 1,948,052 shares [1]. - The offering is anticipated to close on June 27, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds will be utilized for investments and capital expenditures to support national security priorities, including existing programs and high-probability pipeline opportunities [2]. - Funds will also be allocated for targeted acquisitions and general corporate purposes, including debt repayment and offering-related expenses [2]. Group 3: Management and Regulatory Information - Baird, RBC Capital Markets, Truist Securities, and Raymond James are acting as joint book-running managers for the offering, with additional co-managers involved [3]. - The offering is conducted under an automatic shelf registration statement filed with the SEC, which became effective on February 21, 2024 [4].

Core Viewpoint - Lifeward Ltd. has announced a public offering of 4,000,000 ordinary shares and accompanying warrants at a price of $0.65 per share, aiming to raise approximately $2.6 million for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering includes 4,000,000 ordinary shares and warrants to purchase an additional 4,000,000 shares at the same price of $0.65 [1]. - The ordinary warrants will be exercisable immediately and will expire five years from the issuance date [1]. - The expected gross proceeds from the offering are approximately $2.6 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for continuing commercial efforts, working capital, and general corporate purposes [3]. Group 3: Regulatory Information - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 25, 2025 [4]. - A preliminary prospectus has been filed with the SEC and is available on their website [4]. Group 4: Company Overview - Lifeward Ltd. specializes in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [6]. - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [6].

Group 1 - SeaStar Medical Holding Corporation announced a public offering of 6,153,847 shares of common stock at a price of $0.65 per share, with potential additional gross proceeds of up to $4 million from short-term warrants [1][4] - The Series A warrants will expire in five years, while the Series B short-term warrants will expire in 18 months, both having an exercise price of $0.65 per share [2] - The offering is expected to close around June 23, 2025, pending customary closing conditions [2] Group 2 - H.C. Wainwright & Co. is the exclusive placement agent for the offering [3] - The gross proceeds from the offering are anticipated to be approximately $4 million before deducting fees and expenses [4] - The net proceeds will be used for general corporate purposes [4] Group 3 - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first product QUELIMMUNE approved by the FDA in 2024 for acute kidney injury in pediatric patients [7] - The company’s Selective Cytopheretic Device therapy has received Breakthrough Device Designation for six therapeutic indications, facilitating a faster approval process [7] - SeaStar is conducting a pivotal trial for its SCD therapy in adult patients with acute kidney injury, a condition affecting over 200,000 adults in the U.S. annually [7]

Core Viewpoint - Biomea Fusion, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $40 million before expenses, with the offering expected to close on June 20, 2025 [1][2]. Group 1: Offering Details - The offering consists of 19,450,000 shares of common stock and accompanying warrants, along with pre-funded warrants for an additional 550,000 shares [1]. - The combined offering price for each share of common stock and accompanying warrant is set at $2.00, while the pre-funded warrant and accompanying warrant are priced at $1.9999 [1]. - Underwriters have a 30-day option to purchase up to an additional 3,000,000 shares and/or warrants at the public offering price [1]. Group 2: Financial Proceeds - The gross proceeds from the offering are expected to be approximately $40 million, excluding any additional shares or warrants purchased by underwriters [2]. - The offering is subject to customary closing conditions and is anticipated to close on June 20, 2025 [2]. Group 3: Management and Regulatory Information - Jefferies is acting as the sole book-running manager for the offering [3]. - The securities are being offered under an effective shelf registration statement previously filed with the SEC [3].

Core Viewpoint - Processa Pharmaceuticals, Inc. has announced a public offering of 28 million shares of common stock at a price of $0.25 per share, aiming to raise approximately $7 million for clinical trials and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes 28 million shares of common stock or pre-funded warrants, along with common warrants to purchase an additional 28 million shares at an exercise price of $0.25 per share [1]. - The offering is expected to close around June 18, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to continue the Phase 2 clinical trial for NCG-Cap, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing Next Generation Cancer (NGC) therapies that enhance safety and efficacy [5]. - The company's NGC drugs are modifications of existing FDA-approved oncology therapies, aiming to improve the metabolism and distribution of these drugs while retaining their cancer-killing mechanisms [5].

Core Viewpoint - Adial Pharmaceuticals, Inc. has announced a public offering of 11,100,000 shares of common stock and associated warrants, aiming to raise approximately $3.6 million for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes Series D warrants to purchase up to 11,100,000 shares and Series E warrants to purchase up to 8,325,000 shares, priced at a combined offering price of $0.3251 per share [1]. - The Series D and Series E warrants will have an exercise price of $0.35 per share, with Series D warrants expiring five years from stockholder approval and Series E warrants expiring eighteen months from stockholder approval [2]. - The closing of the offering is expected on or about June 18, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Existing Warrants Amendment - The company will amend existing Series B-1 and Series C-1 warrants to reduce their exercise price from $0.74 to $0.35 per share, subject to stockholder approval [4]. Group 4: Company Overview - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting Alcohol Use Disorder (AUD) [7]. - AD04 has shown promising results in a pivotal Phase 3 clinical trial, indicating potential for treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [7].

Core Viewpoint - Castellum, Inc. has successfully closed a public offering of 4,166,667 Units at a price of $1.20 per Unit, raising approximately $5.0 million in gross proceeds for working capital and general corporate purposes [1][2][3]. Group 1: Offering Details - The public offering consisted of Units, each comprising one share of common stock and one warrant to purchase one share of common stock [1]. - The warrants are immediately exercisable at a price of $1.22 per share and will expire 60 days from the date of issuance [1]. - The shares of common stock and warrants are immediately separable and were issued separately [1]. Group 2: Financial Information - Gross proceeds from the offering are approximately $5.0 million before deducting placement agent fees and offering expenses [2]. - The net proceeds will be utilized for working capital and general corporate purposes [2]. Group 3: Regulatory Information - A shelf registration statement on Form S-3 relating to the securities was previously filed with the U.S. Securities and Exchange Commission (SEC) [3]. - The offering was conducted under a preliminary prospectus supplement and an accompanying prospectus that have been filed with the SEC [4].

Core Viewpoint - Chanson International Holding has announced a public offering expected to generate approximately $8 million in gross proceeds to fund the expansion of its store network in China and the U.S. [1][3] Group 1: Offering Details - The offering consists of 16,000,000 units priced at $0.50 per unit, each unit includes one Class A ordinary share or a pre-funded warrant, along with Series A and Series B warrants [2] - Each Series A and Series B warrant has an exercise price of $0.525 per Class A ordinary share and can be exercised starting from the issuance date until two and a half years later [2] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to opening new stores in China and the U.S., with specific allocations depending on market conditions [3] Group 3: Company Overview - Chanson International Holding, founded in 2009, operates bakery, seasonal, and beverage products through its chain stores in China and the U.S., with 63 stores in China and 3 in New York City [5] - The company focuses on providing healthy, nutritious, and ready-to-eat food, utilizing advanced facilities and in-depth industry research to meet customer demand [5]